The HER2-altered cell lines (H2170, Calu-3, and H1781) were found to be sensitive to afatinib, while the HER2- or EGFR-non-dependent NSCLC cells were insensitive, which implied that afatinib was a potential option for NSCLC patients with HER2 alterations [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.